Related Experiment Video
Updated: Jul 3, 2026
08:09
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
Nicotine and Parkinson's disease: implications for therapy
Maryka Quik1, Kathryn O'Leary, Caroline M Tanner
1The Parkinson's Institute, Sunnyvale, California, USA. mquik@parkinsonsinstitute.org
Summary
Nicotine shows promise for Parkinson's disease therapy by potentially protecting against brain damage, improving symptoms, and reducing levodopa side effects. Further research into nicotinic acetylcholine receptor ligands could offer new treatment avenues.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Parkinson's disease is a neurodegenerative disorder with limited therapeutic options.
- Nicotine, a stimulant of nicotinic acetylcholine receptors, has been investigated for potential therapeutic benefits.
Purpose of the Study:
- To review the evidence for nicotine's therapeutic potential in Parkinson's disease.
- To explore nicotine's effects on nigrostriatal damage, disease symptoms, and levodopa-induced dyskinesias.
Main Methods:
- Review of epidemiological studies correlating tobacco use and Parkinson's disease incidence.
- Analysis of experimental research on nicotine's protective effects against neurotoxins.
- Examination of clinical studies on nicotine's symptomatic effects.
- Evaluation of primate studies on nicotine's impact on levodopa-induced dyskinesias.
Main Results:
- Epidemiological data show an inverse correlation between tobacco use and Parkinson's disease.
- Experimental studies indicate nicotine can protect against neurotoxic insults.
- Clinical trials suggest nicotine may offer modest symptomatic benefits.
- Primate studies demonstrate nicotine's ability to reduce levodopa-induced dyskinesias.
Conclusions:
- Nicotine exhibits potential therapeutic benefits for Parkinson's disease, including neuroprotection and symptomatic improvement.
- Nicotine may help manage levodopa-induced dyskinesias, a common complication of Parkinson's treatment.
- Central nervous system-selective nicotinic receptor ligands represent a promising therapeutic strategy for Parkinson's disease.
More Related Videos
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:23Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:27CNS Depressants: Alcohol and Nicotine
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...